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Edited by Veli-Pekka LehtoAbstract TNFa has dramatic eﬀects on iron metabolism
contributing to the generation of hypoferraemia in the anaemia
of chronic disease. Interestingly, TNFa is also synthesised and
released within the intestinal mucosa, suggesting that this pro-
inﬂammatory cytokine may play a role in regulating dietary iron
absorption. To investigate this possibility, we stimulated intes-
tinal Caco-2 cells with TNFa (10 ng/ml). In TNFa-treated cells,
apical iron uptake was signiﬁcantly decreased and this was
accompanied by a reduction in divalent metal transporter protein
and mRNA expression. Our data suggest that TNFa could
regulate dietary iron absorption and that the apical transport
machinery is the target for these actions.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Iron is an essential nutrient in the human diet. Recently, a
number of the key components of the iron transport pathway
in intestinal enterocyte have been elucidated (reviewed in [1]).
However, the ﬁne control of absorption remains unclear. It has
been proposed that overall regulation of dietary iron assimi-
lation is mediated via signals from three distinct compartments
that reﬂect dietary composition, the status of the body iron
stores, and the metabolic requirements – especially for the
production of new red blood cells. These signals are generally
referred to as the dietary, stores, and erythroid regulators,
respectively.
Recently, hepcidin, a 20–25 amino acid peptide produced
in the liver [2,3], has been proposed as one possible mediator
of the stores and erythroid regulatory pathway. However, it
seems likely that a number of other humoral factors may also* Corresponding author. Fax: +44-1483-576978.
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from the diet, including transferrin saturation [4], and the
plethora of cytokines that regulate body iron utilisation [5].
In the present study, we have focussed on the role of one of
these cytokines tumour necrosis factor alpha (TNFa) in
regulating intestinal iron absorption. TNFa is a pro-inﬂam-
matory cytokine and has been implicated in the hypoferra-
emia associated with the anaemia of chronic disease [6,7].
Moreover, both dietary [8] and circulatory iron [9] can in-
ﬂuence TNFa production. The synthesis of TNFa by cells
residing within the intestinal mucosa in response to high iron
intakes [8] raises the intriguing possibility that this cytokine
might play a role as a local dietary regulator of intestinal iron
absorption.
To investigate the possible intestinal interaction between
TNFa and iron transport, we have used the human intestinal
Caco-2 cell line. Caco-2 cells diﬀerentiate spontaneously in
culture taking on an enterocyte-like phenotype expressing a
number of small intestinal brush border enzymes and nutrient
transporters [10,11]. Importantly for our studies, Caco-2 cells
also express the key genes and proteins involved in iron
transport, including divalent metal transporter (DMT1), iron
regulated transporter (IREG1), ferritin, Dcytb and hephaestin
[12–16] and are generally regarded as the best available intes-
tinal cell model for studying the mechanisms associated with
vectorial iron transport.
In the present study, cells were stimulated with TNFa for 72
hours and used to measure changes in iron uptake and eﬄux,
as well as alterations in the expression of the transporters
DMT1 and IREG1 that are responsible for iron transport
across the apical and basolateral membranes, respectively, of
intestinal enterocytes [17–21].2. Materials and methods
2.1. Cell culture
Caco-2 cells (the TC7 subclone used in our previous studies [12–15])
were cultured in a 95% air/5% CO2 atmosphere in Dulbecco’s modiﬁed
Eagle’s minimal essential medium (DMEM), supplemented with 20%
heat-inactivated foetal bovine serum. All experiments were carried out
on cells between passage numbers 35 and 42. For experiments, cells
were seeded at a density of 1 104 cells/cm2 onto Transwell inserts
(Costar UK, Buckinghamshire, UK) and used 21 days later at which
time they were fully diﬀerentiated [10,11,14]. To determine the eﬀects
of TNFa on iron transport and transporter expression, cells were
cultured in the presence or absence of TNFa (10 ng/ml) added to theation of European Biochemical Societies.
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culture period.
2.2. Iron uptake by Caco-2 TC7 cell monolayers
The measurement of iron uptake by Caco-2 TC7 cells has been de-
scribed previously [12]. Brieﬂy, transepithelial pH gradients were
produced using N-2-hydroxyethylpiperazine-N0-2-ethanesulphonic
acid (HEPES)-buﬀered salt solution (pH 7.5; 140 mM NaCl, 5 mM
KCl, 1 mM Na2HPO4, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM glucose,
and 10 mM HEPES) in the basolateral chamber, with 2-(N-morpho-
lino)ethanesulphonic acid (MES)-buﬀered salt solution (pH 5.5 –
substituting MES for HEPES) added to the apical chamber. Uptake
was initiated by the addition of 10 lM Fe2þ complexed with 1 mM
ascorbic acid (freshly prepared prior to the start of each experiment)
and 37 kBq/ml 55FeCl3 to the apical chamber. Previous studies have
shown that a 10–50-fold excess of ascorbate was suﬃcient to maintain
maximal levels of Fe(II) in solution [22]. The reaction was terminated
after 15 min, which is within the linear portion of the iron uptake curve
[12] and cell monolayers were washed 3 times in ice cold transport
buﬀer containing a 10-fold excess of iron, solubilised overnight in 200
mMNaOH, and ﬁnally subjected to scintillation counting to determine
iron uptake. In order to assess basolateral eﬄux, uptake was allowed
to reach equilibrium (after 60 min [12]). Cells were subsequently placed
into fresh uptake buﬀers and incubated for a further 60 min. The level
of iron present in the basolateral medium at the end of this period was
determined by scintillation counting.
2.3. Western blot analysis
Following removal of culture medium, cell monolayers were washed
twice in phosphate buﬀer and harvested from the insert using a cell
scraper. Cells were pelleted by centrifugation at 750 · g for 5 min and
resuspended in 250 ll PBS (containing 0.5 mM PMSF, 0.2 mM
benzamidine and 0.02% NaN3) and homogenised at full power with an
UltraTurrax homogeniser for 2 30 pulses.
Cell homogenates (20 lg) were solubilised in sample buﬀer and
subjected to SDS–PAGE. The proteins were transferred onto nitro-
cellulose (Hybond ECL – Amersham Pharmacia Biotech, Bucking-
hamshire, UK) and blocked overnight in phosphate buﬀer containing
0.05% Tween 20 and 1% fat free milk. The nitrocellulose was incubated
for 2 h at room temperature with commercially available polyclonal
antibodies to DMT1 [both iron responsive element (IRE) and non-IRE
isoforms] and IREG1 (ADI –TX, USA) or villin (Santa Cruz Bio-
technology Inc., CA, USA). Following removal of the primary anti-
body, nitrocellulose ﬁlters were incubated with an HRP-linked
secondary antibody, and cross reactivity visualised using ECL Plus and
Hyperﬁlm ECL (Amersham Pharmacia Biotech) according to the
manufacturer’s instructions. Band densities were semi-quantiﬁed by
densitometric analysis using Scion Image software (Scion Corporation,
MD, USA).
2.4. RT-PCR
Total RNA was isolated from Caco-2 cells using Trizol reagent (Life
Technologies, Paisley, UK) and stored at )70 C in 75% ethanol until
required. Reverse transcription polymerase chain reaction (RT-PCR)
was performed in a single step reaction, using Ready-to-go RT-PCR
Beads (Amersham Pharmacia Biotech) on total RNA samples (1 lg
per tube) using the primer sequences and conditions described
previously [15].
2.5. Cloning of DMT1 promoter and reporter gene studies
Approximately 1.6 kb of the DMT1 promoter was ampliﬁed by PCR
using primers derived from published sequences [23,24] (sense primer:
CAG ACGCGT GGT CCC CGA GTT TTG TTT TTT ACT TCG
CAC; antisense, CAG CTCGAG TTA CCA GCT CCG CAA CCA
CCT G). These primers included restriction sites for MluI and XhoI
(underlined). The ampliﬁed DNA was digested and subcloned into the
MluI-XhoI sites of pGL3 Basic vector (Promega, Southampton, UK),
creating a transcriptional fusion with the luciferase gene. The con-
struct, pGL3NR2S, was sequenced to verify its authenticity.
The pGL3NR2S construct was transfected into pre-conﬂuent Caco-
2 cells using CaPO4 (ProFection, Promega, Southampton, UK) and
the cells were cultured for a further 3 days. On day 3 post-transfection,
the cells were switched to serum-free medium containing TNFa and
cultured for a further 72 h prior to assay for changes in luciferase
activity.2.6. Data analysis
Data are presented as means S.E.M. Statistical analysis was car-
ried out using SPSS statistics package and utilised one-way ANOVA
followed by Tukey’s post hoc test or Student’s unpaired t test where
appropriate. Diﬀerences were considered signiﬁcant at P < 0:05.
2.7. Materials
Radiochemicals and materials for Western blotting were supplied by
Amersham Pharmacia Biotech. Cell culture medium, heat-inactivated
foetal bovine serum and plasticware were purchased from Invitrogen
(Paisley, UK) unless stated. Reagents and plasmids for cell transfec-
tions and reporter gene assays were obtained from Promega, South-
ampton, UK. Human TNFa was purchased from Sigma-Aldrich
(Poole, Dorset, UK). All other chemicals were of highest grade
available and bought from Sigma, Merck or Fluka.3. Results and discussion
It has been proposed that TNFa acts on a number of cell
types to inhibit the release of iron, thereby contributing to
hypoferraemia [25] and that this in turn is mediated by an
increase in ferritin synthesis and subsequent iron sequestration
[26,27]. The intestine may be a target tissue for this action.
TNFa is released from intraepithelial lymphocytes residing
within the intestinal mucosa following increased dietary iron
intake [28] through a mechanism that is thought to involve
HFE on the basolateral surface of the crypt epithelium [29]
and results in iron deposition within intestinal enterocytes via a
TNF receptor 2-dependent mechanism [8]. In an attempt to
elucidate the eﬀects of TNFa on intestinal iron transport and
transporter expression, we have used human intestinal Caco-2
cells exposed to the cytokine for 72 h. The level of TNFa used
in our study (10 ng/ml) was selected because it is in the middle
of the range of TNFa concentrations that have been used in
previous studies on nutrient transport in Caco-2 cells [30,31]
and in earlier in vitro studies on iron metabolism [32,33].
As a starting point for the current investigation, we mea-
sured ferritin protein expression in Caco-2 cells. Consistent
with data from other studies, stimulation of Caco-2 cell with
TNFa signiﬁcantly increased ferritin levels [26,27] (Fig. 1). To
determine whether the changes in cellular ferritin had any
consequences for functional iron transport across the Caco-2
cell monolayer, we measured both iron uptake across the
apical membrane into the cells and eﬄux into the basolateral
medium. Iron uptake (measured over 15 min when uptake was
linear [12]) across the apical membrane was signiﬁcantly de-
creased in Caco-2 cells treated with TNFa compared with
untreated controls (Fig. 2(a)). In parallel experiments, uptake
was allowed to proceed to equilibrium (60 min in these stud-
ies). At this time, uptake was not signiﬁcantly diﬀerent in the
control and TNFa-treated groups (data not shown). Cells were
placed in fresh medium and incubated for a further 60 min to
determine iron eﬄux into the basolateral medium. In cells
treated with TNFa, there was a small but signiﬁcant decrease
in iron eﬄux (Fig. 2(b)). The decrease in iron eﬄux (i.e., in-
creased retention within the cell) could be explained by the
increase in ferritin synthesis and subsequent iron sequestra-
tion. However, we could not rule out the possibility that TNFa
was having direct eﬀects on the eﬄux transporter IREG1. To
investigate this latter possibility, IREG1 protein and mRNA
levels in Caco-2 cells were measured using Western blotting
and RT-PCR, respectively. Expression of the ‘‘housekeepers’’,
villin protein and b-actin mRNA, were unaﬀected by treatment
Fig. 1. Ferritin expression is increased in Caco-2 cells stimulated with
TNFa. Caco-2 cells were grown for 21 days on Transwell inserts and
were stimulated for the ﬁnal 72 h of the culture period with TNFa (10
ng/ml), added to the basolateral medium. Cell homogenates were
subjected to Western blotting using a polyclonal ferritin antibody
(Sigma–Aldrich). Ferritin protein levels were signiﬁcantly increased in
TNFa-treated cells (*P < 0:01). Expression of the housekeeper protein
villin in cell samples was not altered following cytokine treatment.
Densitometry data are meansS.E.M. of three separate experiments.
Fig. 2. Eﬀect of TNFa on iron transport across Caco-2 cell mono-
layers. (a) Iron uptake across the apical membrane of Caco-2 cell
stimulated with TNFa was determined over a 15 min time-course – we
have previously shown that uptake is still linear at this time [10].
Uptake was signiﬁcantly decreased in TNFa-treated cells (*P < 0:001).
(b) In some experiments uptake was allowed to proceed to equilibrium
and cells were placed in fresh medium to monitor eﬄux into the ba-
solateral chamber. There was a small but signiﬁcant decrease in iron
eﬄux from the cell monolayers stimulated with TNFa (**P < 0:01).
Data are means S.E.M. of 6–12 observations.
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with TNFa had no signiﬁcant eﬀect on IREG1 protein or
mRNA expression (Figs. 3(b) and 4(b)). These data are sup-
ported by previous studies demonstrating that while inﬂam-
matory stimuli such as lipopolysaccharide and turpentine
downregulate IREG1 mRNA in the spleen, TNFa has no ef-
fect of transporter expression [34]. Therefore, in the absence of
changes in IREG1 expression in TNFa-treated cells, we con-
clude that the decrease in iron eﬄux is due to increased re-
tention of iron within the cell possibly as a consequence of an
increased rate of ferritin synthesis that could lead to its
sequestration.
To gain an insight into the molecular events underlying the
decrease in iron uptake across the apical membrane of the
Caco-2 cell monolayer, parallel sets of cells were treated with
TNFa and used to generate sources of cellular protein or total
RNA. The commercially available antibodies used in this
study can distinguish between the IRE and non-IRE isoforms
of DMT1. Our data demonstrated that following stimulation
with TNFa the protein expression of IRE-containing isoform
was signiﬁcantly decreased, whereas there was no eﬀect on
DMT1(non-IRE) levels (Fig. 3(c) and (d)). Data from RT-
PCR analysis of RNA from TNFa-treated and control cells
supported the protein studies and showed a signiﬁcant de-crease in DMT1(IRE) mRNA (Fig. 4(c)) but no change in
DMT1(non-IRE) (Fig. 4(d)).
In total, four DMT1 splice variants have been described that
exhibit sequence diﬀerences at either the 30 [24] or 50 end [35] of
the gene. The recently described 50 variants [35] have not been
well-characterised in terms of their function and tissue abun-
dance and therefore our study has focussed on the so-called
exon 1B variants. To determine whether TNFa could alter the
promoter activity of these splice variants, we cloned 1.6 kb of
the 50 ﬂanking region upstream of the transcription start site
into the pGL3 vector upstream of a luciferase reporter and
transfected this construct into Caco-2 cells. Reporter gene
analysis of the common DMT1 50 promoter upstream of exon
1B showed no signiﬁcant eﬀect of TNFa treatment (Fig. 5).
Previous studies using the same reporter-gene construct dem-
onstrated that zinc (which increases DMT1 expression in
Caco-2 cells [13]) strongly increases promoter activity [36],
indicating that the construct is functional. The lack of eﬀect of
TNFa on promoter activity, taken together with the protein
and mRNA data, suggests two possible mechanisms for the
regulation of DMT1 expression. Either the exon 1A promoter
plays a major role in mediating the eﬀects of TNFa – there is
some evidence that this region of the DMT1 gene is important
in the overall response to iron deﬁciency and iron loading in
Fig. 3. Eﬀect of TNFa on iron transporter protein expression in Caco-2 cells. Cell homogenates (20 lg protein) were resolved by SDS–PAGE,
transferred to nitrocellulose membranes and probed with commercially available antibodies to (a) villin – the housekeeper protein, (b) IREG1,
(c) DMT1(IRE) or (d) DMT1(non-IRE). TNFa treatment signiﬁcantly decreased the expression of DMT1(IRE) (*P < 0:03). The expression of the
other proteins was unaltered by TNFa. Densitometry data are meansS.E.M of 3–6 separate observations.
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(UTR) of DMT1 contains the regulatory information. Such a
mechanism would presumably implicate a role for the IRE thatresides in the 30 UTR of one of the DMT1 splice variants [24].
In support of this possible mechanism we demonstrated that
transferrin receptor (TfR) expression, which also contains IRE
Fig. 4. Eﬀect of TNFa on iron transporter mRNA expression in Caco-2 cells. RNA expression of (a) b-actin – control mRNA, (b) IREG1,
(c) DMT1(IRE) or (d) DMT1(non-IRE) in control and TNFa-treated cells were determined by RT-PCR. Products were subjected to electrophoresis
on 1% agarose gels and stained with ethidium bromide. Band intensity was determined by scanning densitometry. TNFa treatment signiﬁcantly
decreased the expression of DMT1(IRE) (*P < 0:005). TNFa had no eﬀect on the expression of the other transporters. Densitometry data are
meansS.E.M of six observations per group.
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treated cells (Fig. 6). However, while other inﬂammatory me-
diators such as lipopolysaccharide and IFNc have been shownto decrease TfR by reducing iron regulatory protein (IRP)
RNA binding activity, there is no similar evidence for a reg-
ulatory role of TNFa on IRP-1 or IRP-2 activity [39]. Thus,
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Fig. 5. DMT1 promoter activity in Caco-2 cells is not altered by
stimulation with TNFa. 1.6 kb of the DMT1 50 ﬂanking region up-
stream of exon 1B was cloned into pGL3 Basic vector, creating a
transcriptional fusion with a luciferase gene. Caco-2 cells were trans-
fected with this construct and stimulated with TNFa (10 ng/ml). In
some experiments, cells were subjected to sham transfection (i.e., no
vector) or transfected with a vector containing the DMT1 promoter in
the antisense conﬁguration. Introduction of the sense promoter in-
duced luciferase activity in Caco-2 cells. However, stimulation of the
cells with TNFa had no further eﬀect on luciferase activity. Data are
meansS.E.M. of 10 separate determinations in each group. Data
bars containing common letter are not signiﬁcantly diﬀerent from each
other (one-way ANOVA and Tukey’s post hoc test).
Fig. 6. Transferrin receptor expression is decreased in Caco-2 cells fol-
lowing stimulationwith TNFa. TfR likeDMT1 contains IRE sequences
in the 30 UTR. Following TNFa stimulation, TfR mRNA expression
was signiﬁcantly decreased in Caco-2 cells (*P < 0:01). There was no
eﬀect of TNFa on mRNA expression of the housekeeper gene b-actin.
Densitometry data are means S.E.M of four experiments.
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mediating the response to TNFa remain to be clariﬁed.
In summary, our data support a regulatory role for TNFa
in iron metabolism. Taken together with previous studies,
there remains the intriguing possibility that TNFa, in ad-
dition to its pro-inﬂammatory actions, could be a physio-logically relevant local regulator of iron absorption
following its liberation from intraepithelial lymphocytes in
response to high dietary iron intake. Furthermore, the spe-
ciﬁc regulation of iron uptake across the apical membrane of
Caco-2 cells together with the decrease in DMT1(IRE) ex-
pression indicates that the control of intestinal iron ab-
sorption is determined by modulation of the apical uptake
machinery.Acknowledgements: This work was funded by project grants from the
Biotechnology and Biological Sciences Research Council (90/D13400)
and The Wellcome Trust. D.J. is supported by a BBSRC studentship.References
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